Tianyu Corporation: Subsidiary's formulated product obtains first FDA approval number in the United States

Tianyu Group announced that its wholly-owned subsidiary, Nuode Pharmaceuticals, has received approval for the new drug abbreviated application of the combination of Olmesartan Medoxomil and Hydrochlorothiazide tablets filed with the US FDA. The drug is mainly used to treat hypertension, was developed by Cosette Pharmaceuticals, Inc, and was launched in the US in June 2003. Nuode Pharmaceuticals' product obtained FDA acceptance in February 2020, with a cumulative investment in research and development of approximately 7.6277 million RMB so far. The approval of Olmesartan Medoxomil and Hydrochlorothiazide tablets by the US FDA marks the first approval of a formulated product and signifies that the company's formulated products have officially obtained market access qualifications in the US, further deepening its overseas business layout.